BiotechTube

Vancomycin + Daptomycin

ApprovedTerminated
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Bacteremia

Conditions

Bacteremia

Trial Timeline

Jun 1, 2011 → Jan 1, 2012

NCT ID
NCT01287832

About Vancomycin + Daptomycin

Vancomycin + Daptomycin is a approved stage product being developed by Merck for Bacteremia. The current trial status is terminated. This product is registered under clinical trial identifier NCT01287832. Target conditions include Bacteremia.

What happened to similar drugs?

1 of 4 similar drugs in Bacteremia were approved

Approved (1) Terminated (2) Active (1)
✅Daptomycin + ComparatorMerckApproved
❌Ceftolozane-Tazobactam + MeropenemMerckPhase 3
❌Cefazolin IV + Linezolid IV + Vancomycin (IV)PfizerPhase 3
🔄Ceftobiprole medocaril + DaptomycinBasilea PharmaceuticaPhase 3

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01287832ApprovedTerminated

Competing Products

9 competing products in Bacteremia

See all competitors
ProductCompanyStageHype Score
Daptomycin + ComparatorMerckApproved
43
Daptomycin for InjectionMerckPhase 2
35
Ceftolozane-Tazobactam + MeropenemMerckPhase 3
32
Cefazolin IV + Linezolid IV + Vancomycin (IV)PfizerPhase 3
32
Aurexis®Bristol Myers SquibbPhase 2
35
ceftobiprole medocarilBasilea PharmaceuticaPhase 2
21
Ceftobiprole medocaril + DaptomycinBasilea PharmaceuticaPhase 3
34
AP-SA02Armata PharmaceuticalsPhase 1/2
22
514G3 (2 mg/kg) plus standard IV antibiotic treatment + 514G3 (10 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase IIXBiotechPhase 1/2
22